Drug-induced nephrolithiasis: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System

Drug-induced nephrolithiasis is a recognized complication in clinical practice. The objective of this study is to identify drugs that are significantly associated with an increased risk of inducing nephrolithiasis based on the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).